IL2 and amyotrophic lateral sclerosis: Suppressing activated myeloid cells with CTLA4-Ig (Abatacept/Orencia ®), which binds to CD80 and CD86 and prevents interaction with CD28, in combination with subcutaneous low dose IL-2 could improve Treg survival and function in ALS.